Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.30 |
| ▸ | PTAFR | P25105 | 1/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15068353 | 1.00 | ERN1 (0.33) | ERN1HTR2ANPSR1ALDH1A1HTR2C | |
| SCHEMBL30078149 | 0.84 | ALDH1A1 (0.34) | ERN1ALDH1A1 | |
| SCHEMBL15065242 | 0.84 | ALDH1A1 (0.34) | ERN1ALDH1A1 | |
| SCHEMBL22104956 | 0.79 | HTR2A (0.35) | HTR2AALDH1A1HTR2CKCNH2TRIM24 | |
| SCHEMBL30078081 | 0.74 | IRAK4 (0.31) | ALDH1A1 | |
| SCHEMBL15066253 | 0.74 | IRAK4 (0.46) | — | |
| SCHEMBL30078125 | 0.74 | IRAK4 (0.46) | — | |
| SCHEMBL15065233 | 0.74 | IRAK4 (0.31) | ALDH1A1 | |
| SCHEMBL22104915 | 0.74 | L3MBTL1 (0.40) | ERN1NPSR1ALDH1A1 | |
| SCHEMBL15065636 | 0.73 | TRIM24 (0.41) | HTR2ANPSR1HTR2CKCNH2TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ERN1 2775/4885HTR2A 1942/4885NPSR1 4389/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ERN1 2775/4885HTR2A 1942/4885NPSR1 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.